Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis
Abstract Background The sensitivity and specificity of minimal residual disease detected by circulating tumor DNA profiling (ctDNA MRD) in lung cancer, with particular attention to the distinction between landmark strategy and surveillance strategy, for predicting relapse in lung cancer patients aft...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-023-02849-z |
| _version_ | 1827948095430721536 |
|---|---|
| author | Ran Zhong Rui Gao Wenhai Fu Caichen Li Zhenyu Huo Yuewen Gao Yi Lu Feng Li Fan Ge Hengjia Tu Zhixuan You Jianxing He Wenhua Liang |
| author_facet | Ran Zhong Rui Gao Wenhai Fu Caichen Li Zhenyu Huo Yuewen Gao Yi Lu Feng Li Fan Ge Hengjia Tu Zhixuan You Jianxing He Wenhua Liang |
| author_sort | Ran Zhong |
| collection | DOAJ |
| description | Abstract Background The sensitivity and specificity of minimal residual disease detected by circulating tumor DNA profiling (ctDNA MRD) in lung cancer, with particular attention to the distinction between landmark strategy and surveillance strategy, for predicting relapse in lung cancer patients after definitive therapy has yet to be determined. Methods The prognostic value of ctDNA MRD by landmark strategy and surveillance strategy was evaluated in a large cohort of patients with lung cancer who received definitive therapy using a systemic literature review and meta-analysis. Recurrence status stratified by ctDNA MRD result (positive or negative) was extracted as the clinical endpoint. We calculated the area under the summary receiver operating characteristic curves, and pooled sensitivities and specificities. Subgroup analyses were conducted based on histological type and stage of lung cancer, types of definitive therapy, and ctDNA MRD detection methods (detection technology and strategy such as tumor-informed or tumor-agnostic). Results This systematic review and meta-analysis of 16 unique studies includes 1251 patients with lung cancer treated with definitive therapy. The specificity of ctDNA MRD in predicting recurrence is high (0.86–0.95) with moderate sensitivity (0.41–0.76), whether shortly after treatment or during the surveillance. The landmark strategy appears to be more specific but less sensitive than the surveillance strategy. Conclusions Our study suggests that ctDNA MRD is a relatively promising biomarker for relapse prediction among lung cancer patients after definitive therapy, with a high specificity but suboptimal sensitivity, whether in landmark strategy or surveillance strategy. Although surveillance ctDNA MRD analysis decreases specificity compared with the landmark strategy, the decrease is minimal compared to the increase in sensitivity for relapse prediction of lung cancer. |
| first_indexed | 2024-04-09T12:50:03Z |
| format | Article |
| id | doaj.art-f6423742605143019a8c34a55af4f349 |
| institution | Directory Open Access Journal |
| issn | 1741-7015 |
| language | English |
| last_indexed | 2024-04-09T12:50:03Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj.art-f6423742605143019a8c34a55af4f3492023-05-14T11:19:21ZengBMCBMC Medicine1741-70152023-05-0121111210.1186/s12916-023-02849-zAccuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysisRan Zhong0Rui Gao1Wenhai Fu2Caichen Li3Zhenyu Huo4Yuewen Gao5Yi Lu6Feng Li7Fan Ge8Hengjia Tu9Zhixuan You10Jianxing He11Wenhua Liang12Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical UniversityNanshan School, Guangzhou Medical UniversityDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical UniversityDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical UniversityNanshan School, Guangzhou Medical UniversityNanshan School, Guangzhou Medical UniversityNanshan School, Guangzhou Medical UniversityDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical UniversityFirst Clinical School, Guangzhou Medical UniversityNanshan School, Guangzhou Medical UniversityNanshan School, Guangzhou Medical UniversityDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical UniversityDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical UniversityAbstract Background The sensitivity and specificity of minimal residual disease detected by circulating tumor DNA profiling (ctDNA MRD) in lung cancer, with particular attention to the distinction between landmark strategy and surveillance strategy, for predicting relapse in lung cancer patients after definitive therapy has yet to be determined. Methods The prognostic value of ctDNA MRD by landmark strategy and surveillance strategy was evaluated in a large cohort of patients with lung cancer who received definitive therapy using a systemic literature review and meta-analysis. Recurrence status stratified by ctDNA MRD result (positive or negative) was extracted as the clinical endpoint. We calculated the area under the summary receiver operating characteristic curves, and pooled sensitivities and specificities. Subgroup analyses were conducted based on histological type and stage of lung cancer, types of definitive therapy, and ctDNA MRD detection methods (detection technology and strategy such as tumor-informed or tumor-agnostic). Results This systematic review and meta-analysis of 16 unique studies includes 1251 patients with lung cancer treated with definitive therapy. The specificity of ctDNA MRD in predicting recurrence is high (0.86–0.95) with moderate sensitivity (0.41–0.76), whether shortly after treatment or during the surveillance. The landmark strategy appears to be more specific but less sensitive than the surveillance strategy. Conclusions Our study suggests that ctDNA MRD is a relatively promising biomarker for relapse prediction among lung cancer patients after definitive therapy, with a high specificity but suboptimal sensitivity, whether in landmark strategy or surveillance strategy. Although surveillance ctDNA MRD analysis decreases specificity compared with the landmark strategy, the decrease is minimal compared to the increase in sensitivity for relapse prediction of lung cancer.https://doi.org/10.1186/s12916-023-02849-zctDNAMRDLung cancerLiquid biopsyDiagnostic accuracy |
| spellingShingle | Ran Zhong Rui Gao Wenhai Fu Caichen Li Zhenyu Huo Yuewen Gao Yi Lu Feng Li Fan Ge Hengjia Tu Zhixuan You Jianxing He Wenhua Liang Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis BMC Medicine ctDNA MRD Lung cancer Liquid biopsy Diagnostic accuracy |
| title | Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis |
| title_full | Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis |
| title_fullStr | Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis |
| title_full_unstemmed | Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis |
| title_short | Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis |
| title_sort | accuracy of minimal residual disease detection by circulating tumor dna profiling in lung cancer a meta analysis |
| topic | ctDNA MRD Lung cancer Liquid biopsy Diagnostic accuracy |
| url | https://doi.org/10.1186/s12916-023-02849-z |
| work_keys_str_mv | AT ranzhong accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT ruigao accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT wenhaifu accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT caichenli accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT zhenyuhuo accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT yuewengao accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT yilu accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT fengli accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT fange accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT hengjiatu accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT zhixuanyou accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT jianxinghe accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis AT wenhualiang accuracyofminimalresidualdiseasedetectionbycirculatingtumordnaprofilinginlungcancerametaanalysis |